Adverse Effects of Trichothiodystrophy DNA Repair and Transcription Gene Abnormalities on Human Fetal Development by Roxana  Moslehi et al.
Study Population. Obligate heterozygote mothers of all TTD patients   
studied at the NIH between 2001-2006 (N=15)
 Detailed Reproductive Epidemiologic Questionnaire
Medical and Birth Records
Multi-generation Pedigrees
 Biological Samples
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The effects of DNA repair and transcription genes in human prenatal life have never been 
studied. Trichothiodystrophy (TTD) is a rare (affected frequency of 10-6) recessive disorder 
caused by mutations in genes involved in the nucleotide excision repair (NER) pathway and in 
transcription. Based on clinical observations, we conducted a genetic epidemiologic study to 
investigate gestational outcomes associated with TTD. We compared pregnancies resulting in 
TTD-affected offspring (N=24) with respect to abnormalities in their antenatal and neonatal 
periods to pregnancies resulting in their unaffected siblings (N=18), accounting for correlation, 
and to population reference values. Significantly higher incidence of several severe gestational 
complications was noted in TTD-affected pregnancies. Small for gestational age (SGA<10th
percentile) (RR=9.3, P=0.02), SGA<3rd percentile (RR=7.2, P=0.04), and neonatal intensive care 
unit (NICU) hospitalization (RR=6.4, P=0.02) occurred more frequently among TTD-affected 
neonates compared to their unaffected siblings. Compared to reference values from general 
obstetrical population, pregnancies that resulted in TTD-affected infants were significantly 
more likely to be complicated by hemolysis, elevated liver enzymes, and low platelets (HELLP) 
syndrome (RR=35.7, P=0.0002), elevated mid-trimester maternal serum human chorionic 
gonadotropin (hCG) levels (RR=14.3, P<0.0001), SGA<3rd percentile (RR=13.9, P<0.0001), 
preterm delivery (<32 weeks) (RR=12.0, P<0.0001), pre-eclampsia (RR=4.0, P=0.006), and 
decreased fetal movement (RR=3.3, P=0.0018). Gestational complications were noted in nearly 
all pregnancies resulting in TTD-affected offspring with XPD and TTDN1, but not TTD-A, gene 
mutations. Abnormal placental development may explain the constellation of observed 
complications; therefore, we hypothesize that some TTD genes play an important role in 
normal placental and fetal development. We investigated this hypothesis by analyzing the 
expression patterns of the four TTD genes identified to date. Using EST Profile Viewer (NCBI), 
we determined expression of all four genes in human placenta. We found high expression of all 
TTD genes in placenta, above the mean of their expression in all organs. All genes appeared to 
be in the higher range of their expression in placenta than in skin. Expression of TTDA was 
strongly negatively correlated (r=-0.7,P<0.0001) with gestational age, while XPD, XPB and 
TTDN1 were consistently expressed from 14 to 40 weeks gestation. Conclusion Our results 
indicate an important role for XPD, XPB and TTDN1 gene products during normal human 
placental and fetal development.
Characteristics of  Families, Pregnancies, and Outcomes
a Twins (1 affected, 1 unaffected)
bTwins (both affected) died shortly after birth
cDecreased fetal activity at 15-16 weeks and induced delivery at 21 weeks due to intrauterine fetal demise
Features of  Pregnancies Resulting in Live Births (N=42) 
of  Carrier Mothers (N=15)
a Human chorionic gonadotropin (hCG) levels were elevated in all six. Alpha-fetoprotein levels were 
elevated in one and reduced in three of  the affected pregnancies.
a Elevated hCG; Pre-eclampsia; HELLP; Decreased fetal movement; All others based on 1996 US 
population rates
b Values for Birth Weight are Mean SD
Comparison of  TTD-Affected Pregnancy Characteristics 
to Reference Values 
Affected (n=24) 
N (%)
Unaffected (n=18) 
N (%)
RR (95% CI) P-Value
Gender
Male 13(54.2) 10 (55.6) 1.0 (0.6-1.7) 1.00
Female 11 (45.8) 8 (44.4)
Twin Births
Yes 3 (12.5) 1 (5.6) 2.0 (0.2-20.7) 0.57
No 21 (87.5) 17 (94.4)
Pre-eclampsia
Yes 7 (25.0) 1 (5.6) 5.2 (0.4-61.3) 0.19
No 17 (70.8) 17 (94.4)
Hemolysis, Elevated Liver Enzymes and Low Platelets (HELLP) Syndrome
Yes 3 (12.5) 0
No 21 (87.5) 18 (100.0)
Decreased Fetal Movement Reported by Mother to Physician
Yes 9 (37.5) 1 (5.6) 6.3 (0.9-45.0) 0.07
No 15 (62.5) 17 (94.4)
Abnormal Levels of Maternal Serum Screening Markers (n=11)
Yes 6 (85.7)
a
0
No 1 4 (100.0)
Pre-term Delivery (<37 weeks gestation)
Yes 11 (45.8) 2 (11.1) 2.9 (1.0-8.8) 0.06
No 13 (54.2) 16 (88.9)
Low Birth Weight (<2500 grams)
Yes 15 (62.5) 2 (11.1) 3.5 (1.1-11.0) 0.03
No 9 (37.5) 16 (88.9)
Small for Gestational Age (SGA) (<10
th
percentile)
Yes 13 (54.2) 1 (5.6) 9.3 (1.4-60.5) 0.02
No 11 (45.8) 17 (94.4)
SGA (<3
rd
percentile)
Yes 10 (41.7) 1 (5.6) 7.2 (1.1-48.1) 0.04
No 14(58.3) 17(94.4)
Neonatal Intensive Care Unit (NICU) Hospitalization
Yes 15 (62.5) 1 (5.6) 6.4 (1.4-29.5) 0.02
No 9 (37.5) 17 (94.4)
Affected (n=24) 
N (%)                       
Reference 
Values
a
(%)                       
RR (95% CI) P-Value
Gender                                                          
Male 13 (54.2) (51.1) 1.1 (0.7-1.4) 0.84
Female 11 (45.8) (48.9)
Twin Gestation
3 (12.5) (2.6) 5.5 (1.7-12.0) 0.023
Delivery
Vaginal 15 (62.5) (78.7)
Cesarean 9 (37.5) (20.5) 1.9 (1.0-2.8) 0.072
Hemolysis, Elevated Liver Enzymes and Low Platelets (HELLP) Syndrome
3 (12.5) (0.35) 35.7 (7.6-92.5) 0.0002
Elevated Human Chorionic Gonadotropin (hCG) on Maternal Serum Screening (n=7)
6 (85.7) (6) 14.3 (7.0-16.6) <0.0001
Birth Weight
b
2215 ± 990.1 g 3353 ± 581 g <0.0001
Low Birth Weight (<2500 grams)
15 (62.5) (6.9) 9.2 (6.2-11.5) <0.0001
Very Low Birth Weight (<1500 grams)
5 (20.8) (1.4) 16.3 (6.7-29.5) <0.0001
Small for Gestational Age (SGA)
<10th percentile 13 (54.2) (10) 5.4 (3.3-7.4) <0.0001
<3rd percentile 10 (41.7) (3) 13.9 (7.4-21.1) <0.0001
Preterm Delivery
<37 weeks 11 (45.8) (10.9) 4.3 (2.6-6.0) <0.0001
<32 weeks 5 (20.8) (1.9) 12.0 (4.9-21.6) <0.0001
Pre-eclampsia (n=23)
6 (26.1) (6.5) 4.0 (1.6-7.4) 0.006
Decreased Fetal Movement
9 (37.5) (11.5) 3.3 (1.6-5.2) 0.0018
 TTD is rare (affected frequency of 1 in 106 in Europe) autosomal recessive disorder of DNA 
repair.
 TTD is characterized by:
 Sulphur deficient brittle hair
 Small stature
Mental retardation
 Ichthyotic skin
 Unusual facial features
Photosensitivity in some cases
 Photosensitive TTD caused by mutations in XPD (ERCC2) and XPB (ERCC3) which code for the 
two helicase subunits of transcription factor TFIIH and TTD-A (TFB5) 
which codes for the 10th subunit of TFIIH.
 TFIIH has various roles in several pathways
including nucleotide excision repair (NER), basal 
transcription and activated transcription.
 Non-photosensitive TTD has been associated with 
mutations in TTDN1 (C7ORF11), a gene of unknown 
function 
Mutations in genes coding for other NER proteins may
Lead to other NER disorders besides TTD:
 Xeroderma Pigmentosum [XPA – XPG, XPV]
 Cockayne Syndrome                                   [CS-A, CS-B]
 Cerebro-oculo-facial Syndrome (COFS)   [XPD, CS-B]
 XP/TTD [XPD]
 COFS/TTD [XPD]
 Our systematic genetic epidemiologic investigation indicated a 
greatly increased risk of many adverse pregnancy outcomes such 
as small for gestational age, HELLP syndrome, pre-eclampsia, 
preterm delivery, and decreased fetal movement associated with 
mutations in TTD genes.
 Abnormal placental development can explain the constellation 
of complications noted in our study.
We hypothesize that TTD genes, in particular XPD, XPB and 
TTDN1 are important for normal placental development.
Family ID
Age of mother 
at birth of first 
affected child 
(yr)
Phenotype of 
Affected 
Children
Number of 
Pregnancies 
Resulting in an 
Affected 
Number of 
Affected Live 
births 
Number of 
Unaffected 
Live births 
Number of 
Miscarriages Stillbirth 
R01 26 TTD 1 1 0 2 0
R02 28 TTD 1 1 1 0 0
R03 28 TTD 1 1 1 0 0
R04 31 TTD 3 3 0 0 0
R05 19 TTD 1 1 1 0 0
R06 23 TTD 1 1 1 1 0
R07 23 TTD 1 1 1 0 0
R08 31 TTD 2a 2a 1a 0 0
R09 30 TTD 2b 3b 2 0 0
R10 25 TTD 1 1 1 1 0
R11 23 TTD 2 2 0 0 0
R12 21 XP/TTD 4 4 4 3 1c
R13 25 TTD 1 1 3 0 0
R14 36 TTD 1 1 2 1 0
R15 25 COFS/TTD 1 1 0 0 0
Total 23 24 18 8 1
http://www.scalyskin.org/userimages/TTD2.jpg
STUDY CONCEPTION and HYPOTHESIS
OBJECTIVE
Based on clinical observations by 
Dr. Moslehi, we designed a genetic 
epidemiologic study to investigate 
pregnancy and gestational outcomes 
associated with TTD in order to test the 
hypothesis of involvement of TTD 
genes in human fetal development.
 Compare pregnancies resulting in TTD-affected offspring with respect to 
abnormalities noted during their antenatal and neonatal periods to:
 Pregnancies resulting in unaffected siblings of TTD offspring
 Population (general obstetrical) reference values
 Analyze expression Patterns of TTD genes in various tissues including placenta.
SUMMARY OF FINDINGS
 Highly significant increased risk of the following gestational 
complications associated with pregnancies resulting in nearly all 
TTD and COFS/TTD offspring:
 Pre-term birth
 Low birth weight
Small for gestational age
 Pre-eclampsia
 HELLP syndrome
 Elevated hCG levels
 Decreased fetal movement
Proposed Mechanism: Abnormal Placental Development?
 High expression of XPD, XPB, and TTDN1 in placenta from 14 to 
40 weeks of gestation, above the mean of their expression in all 
other organs including skin.
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